TherapeuticsMD Announces Multiple Presentations Related to Imvexxy and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society - Seite 2

 

Posters

Date: October 4, 2018 Time: 6:00-7:00 pm   Title: Physical Characteristics of TX-004HR: An Ultra-Low-Dose (4- and 10-µg) Estradiol Softgel Capsule Vaginal Insert   Title: A 17β-Estradiol, Softgel, Vaginal Capsule (TX-004HR) Demonstrated an Early Onset of Action for Treating Vulvar and Vaginal Atrophy (VVA) and Moderate-to-Severe Dyspareunia   Title: Systemic Estradiol Levels with Low-Dose Vaginal Estrogens May Differ by Dose and by Product   Title: Correlations of Serum Estradiol and Estrone Concentrations with Menopausal Outcomes and Bleeding   Title: Effects of Single-Capsule 17β-Estradiol/Progesterone (TX-001HR) on Weight and Blood Pressure in Menopausal Women of the REPLENISH Trial   Title: Estradiol and Progesterone Bioavailability for Moderate-to-Severe Vasomotor Symptom Treatment and Endometrial Protection with the Continuous-Combined Regimen of TX-001HR (Oral Estradiol and Micronized Progesterone Capsules)   Title: TX-001HR is Associated with a Clinically Meaningful Effect on Severity of Moderate-to-Severe Vasomotor Symptoms in the REPLENISH Trial  

About Imvexxy

Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Imvexxy is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg dose representing the lowest approved dose of vaginal estradiol available. The full prescribing information may be viewed by visiting www.Imvexxy.com.